CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia

CD70 is a promising target for immunotherapy because it is overexpressed in T-cell lymphoma (TCL) and acute myeloid leukemia (AML) tumor cells but is found in deficient levels in normal tissues and hematopoietic stem cells. This study aims to evaluate the safety and efficacy of CD70-targeted CAR-NK (CD70-CAR-NK) cells in patients with relapsed and refractory TCL and AML.

Trial Details

NCT ID

NCT06696846

Phase

PHASE1

Sponsor

Second Affiliated Hospital, Zhejiang University, School of Medicine

Status

RECRUITING

Cancer Type

Leukemia

Interventions

CD70 CAR-NK

Locations (sample)

Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

According to the WHO disease classification, patients with relapsed/refractory T - lymphoma and acute myeloid leukemia:
Voluntarily participate in this study and sign the informed consent form;
Aged between 18-75 years old, both male and female are eligible;
Relapsed/refractory T cell lymphoma is defined as: relapsed/refractory after having received at least two or more lines of previous treatment (pati…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →